Bioflavonoids represent a class of naturally occurring plant pigments that humans consume daily in gram quantities (1, 2) . A high correlation exists between the intake of bioflavonoid-rich diets and a lower incidence of stomach, colon, breast, and prostate cancer in man (3) (4) (5) (6) (7) . For these reasons, some investigators have suggested that consumption of weakly estrogenic isoflavonoids such as equol, daidzein, and coumestrol may prevent estrogen-dependent breast and prostate cancers by competing with more active, endogenous estrogens such as estradiol for estrogen receptor (ER) in these target tissues (5) (6) (7) . Conversely, studies by our laboratory and others have shown that flavonoids such as luteolin and quercetin bind with high affinity (Kd 1-5 nM) to nuclear type II [3H]estradiol binding sites, but not ER, and this is correlated with the antagonism of estrogenic response in the rat uterus, the inhibition of breast, ovarian, pancreatic, and colon cancer cell proliferation in vitro and estrogen-independent mammary tumor growth in mice (8) (9) (10) (11) (12) (13) . Therefore, it is not surprising that a naturally occurring flavonoid metabolite, methyl p-hydroxyphenyllactate (MeHPLA), has been identified as an endogenous cellgrowth-regulating agent and the natural ligand for the type II site (14) . On the basis of these studies demonstrating mixed agonist/antagonist (estrogenic/antiestrogenic) activities of flavonoids and isoflavonoids in estrogen-responsive tissues, it is likely that dietarily derived flavonoids and/or their metabolites which interact either with ER or type II sites may profoundly affect reproductive function and the incidence of estrogen-dependent breast and prostate cancer (3-. Although isoflavonoids such as coumestrol have demonstrated estrogenic activity in a variety of experimental systems, most of these studies involved feeding these compounds to intact animals for periods of time ranging from days to weeks and subsequently determining uterine wet and/or dry weights (15) (16) (17) (18) (19) . Consequently, the uterotropic response profiles to phytoestrogens have not been extensively evaluated in ovariectomized animals, in which the contribution of ovarian steroids to the overall net uterine hypertrophy, hyperplasia, and DNA synthesis has been eliminated. Recent studies have shown that oral administration of coumestrol to intact, immature rats failed to antagonize estrogenic stimulation of uterine growth, and, in fact, coumestrol treatment increased uterine weight in these studies, suggesting that this isoflavonoid possessed estrogenic activity (15) (16) (17) . However, because these studies involved the treatment of intact, immature female mice with coumestrol over a period of days, it is possible that coumestrol modulated gonadotropin secretion and/or ovarian steroidogenesis, which may have been partially responsible for the observed estrogenic response. A recent report by Yamazaki (20) demonstrating that the isoflavonoid ipriflavone is estrogenic in intact, but not ovariectomized, immature rats also supports this hypothesis (20) .
Our studies described here were designed to assess the estrogenic activity of parenterally and orally administered coumestrol in the immature, ovariectomized rat to rule out the effects of ovarian estrogen on uterotropic response patterns. These data demonstrate that at the dose levels and treatment conditions used, coumestrol behaved as an atypical estrogen, failing to cause significant cytosolic-depletion and nuclear accumulation of ER or uterine hyperplasia and DNA synthesis in the ovariectomized rat, even though uterine wet and dry weights were elevated above control levels. Therefore, the true estro- 20 min in a Beckman GH-3 rotor to obtain the low-speed cytosol (supernatant) and nuclear pellet fractions (21, 22 (21, 22) . Results were expressed as ER sites per cell assuming that mammalian tissues contain approximately 7 pg of DNA per cell nucleus (23) . Uterine DNA content was estimated by the method of Burton (24) .
In studies where the binding affinity of the various phytoestrogens for ER was assessed, uterine cytosol fractions from ovariectomized rats were prepared exactly as described above and diluted to 20 mg/mL in TE buffer containing 10 mM dithiothreitol. After preincubation (140 min at 40C) in the presence of reducing agent to eliminate interference from cytosol type II sites (21) , aliquots of the cytosol were incubated (370C for 30 these studies in the absence (100% bound) or presence of the competitor as previously described (8) . In a typical experiment, 100% bound represented approximately 5000 cpm.
Assessment of isoflavonoid binding affinity for nuclear type II sites. Since nuclear type II site stimulation appears to be involved in target cell response to estrogenic hormones, and flavonoids such as luteolin, quercetin, and pelargonidin appear to inhibit cellular proliferation through type II site binding interactions (8), we determined the binding affinities of isoflavonoids such as coumestrol, daidzein, and genistein for type II sites in rat uterine nuclei. For these studies, uterine nuclear fractions from estradiol-implanted rats (8) were prepared in TE buffer, diluted to a final volume equivalent to 20 mg uterine wet weight equivalents/mL, and incubated (40C for 60 minutes) in the presence of 20 nM [3H]estradiol ± the indicated concentrations of competitor (1.0 nM-20.0 pM) as described in the figure legends. After incubation, the nuclear suspensions were washed by resuspension in TE buffer and centrifugRation to remove free steroid, and bound [ H]estradiol was determined by liquid scintillation counting exactly as previously described (8) mined on the basis of uterine DNA content (sites/cell) as previously described in detail (23) . DNA was estimated by the method of Burton (24) . Statistical analyses. Where indicated, the experimental results are expressed as the mean ± SEM. The data presented in the various figures in this manuscript were analyzed statistically by the appropriate one-way or two-way analysis of variance (fixed treatment models) and Duncan's new multiple range test on the treatment means as described in detail (26) .
Results
To correlate phytoestrogen binding interactions with biological response, we evaluated the binding affinities of these compounds with ER and type II sites in rat uterine nuclear fractions. The data in Figure 1 demonstrate that coumestrol (Kd -180 nM), daidzein (Kd >1000 nM), and genistein (Kd -180 nM) bind to the ER ( Fig. IA) with relatively low affinities as described by numerous laboratories for various tissues (16, 26) . This is consistent with the fact that these compounds are weak or short-acting estrogens with substantially less biological activity than long-acting estrogens such as estradiol (28 nM), daidzein (Kd -5 nM), and genistein (Kd -5 nM) displayed higher binding affinities for type II sites than for the ER (Fig. 1) , and the apparent binding affinities of these three isoflavonoids for nuclear type II sites are similar to those determined for luteolin and quercetin, which bind to nuclear type II sites (but not ER) with very high affinity (Ad -1-5 nM) and inhibit estrogen stimulation of uterine growth in the rat and mammary tumor growth in the mouse (8, 9) . Because coumestrol displayed higher affinity for ER than daidzein and has recently been described as an estrogen in the intact, immature female rat, we focused our efforts on the characterization of the estrogenic activity of coumestrol in the immature, ovariectomized rat uterine model system. Dose-response studies demonstrated that a single injection of coumestrol in doses ranging from 50 to 200 pg resulted in a significant increase in uterine wet weight relative to control (Fig.  2) , and the response obtained with 100-200 pg of coumestrol was equivalent to that obtained after a single injection of 1 pg estradiol-17f9. Therefore, it appeared that in the immature, ovariectomized rat, coumestrol treatment increased uterine wet weight 24 hr after a single injection in a manner similar to that described for longacting estrogens such as estradiol (28, 29) .
The data in Figure 3 represent the temporal effects of coumestrol on uterine wet weight and DNA content after the injection of 100 pg of this phytoestrogen. As expected, based on previous studies suggesting that coumestrol has estrogenic activity (15-1/), uterine wet weight was increased within 4 hr after coumestrol treatment, and this response was sustained for 24 hr, declining to control levels by 62 ing uterine wet weight beyond 24 hr after injection is typically associated with the stimulation of cellular DNA synthesis and true uterine growth (29) . Much to our surprise, even though coumestrol treatment increased uterine wet and dry weights in a manner similar to that obtained with estradiol, it failed to increase uterine DNA content at 24 hr after injection. These findings suggest that in the immature, ovariectomized rat, coumestrol behaves as an atypical estrogen, which stimulates cellular hypertrophy and perhaps protein synthesis without stimulating cellular hyperplasia, reflected by a doubling in DNA content (29) . Therefore, coumestrol mimics estriol, estrone, and estradiol-17ct in this model system by behaving as a short-acting estrogen, capable of stimulating cellular hypertrophy and not hyperplasia when administered as a single injection (28) (29) (30) (31) .
We also assessed the effects of multiple injections of this phytoestrogen on uterine wet weight and DNA content 24 hr after the last injection (Fig. 4) because estriol and estradiol-17(x have been shown to stimulate uterine cellular hypertrophy and hyperplasia in the intact immature (29) or adult-ovariectomized (28, 30, 31) rats when administered by multiple injection or pellet implant. Therefore, we expected that similar results would be obtained after multiple injections of coumestrol. The data in Figure 4 clearly demonstrate that this was not the case. Although multiple injections of coumestrol increased uterine wet weight relative to control, this response was not equivalent to that after following a single injection of 1 pg estradiol (Fig. 4A) (32) (33) (34) , the assessment of ER dynamics (cytosolic ER depletion and nuclear ER accumulation) after estrogen administration can be used to assess the estrogenicity of a variety of compounds (29, 34) . In the present studies, we injected immature, ovariectomized rats with a dose (100 pg) of coumestrol, which substantially increased uterine wet weight without causing cellular hyperplasia (Fig. 4) and the levels of cytosolic and nuclear ER were measured as a function of time after treatment (Fig. 5) 25 tion in the rat uterus in immature, ovariectomized rats. The data in Figure 6 clearly demonstrate that the cytosolic ER depletion and nuclear ER retention patterns after estradiol injection were exactly as described by our laboratory and others for the rat uterine model system under a variety of experimental conditions (29, (35) (36) (37) (38) (39) (40) (41) and the level of cytosolic ER did not return to control levels (0 hours) until 16-24 hr after treatment. It is this sustained cytosolic ER depletion and nuclear ER occupancy that correlates with estrogenic stimulation of cellular hyperplasia and DNA synthesis (28, 29) . The failure of coumestrol to mimic these ER dynamics is likely responsible for the inability of this phytoestrogen to stimulate DNA synthesis in these studies. However, again, in this second experiment, coumestrol treatment did not cause cytosolic depletion or nuclear ER accumulation/retention even though cytosolic ER levels were elevated two-to threefold above time zero controls by 24 hr.
The aforementioned experiments suggested that coumestrol was an atypical estrogen when administered subcutaneously. Therefore, we evaluated the sustained effects of this compound on uterine growth in the rat after oral administration in the drinking water. These studies demonstrated that 96 hr after treatment, orally administered coumestrol resulted in a dose-dependent increase in uterine wet and dry weight relative to controls at dose levels ranging from 5 to 100 pg/mL. Uterine wet and dry weights were essentially doubled by treatment with 100 pg of coumestrol/mL drinking water (-60 mg/kg body weight/day; Fig. 7 ). Time studies with the higher dose level of coumestrol (100 pg/mL drinking water) demonstrated that the uterotropic response peaked between 72 and 96 hr after treatment, and uterine wet and dry weights were increased 20, 000 LUMMu iuiOl five-to sixfold relative to the time-zero vehicle controls (Fig. 8) . More important, however, was the observation that uterine DNA content 72 hr after coumestrol treatment (242 pg/uterus) was nearly equivalent to the control value (217 pg/uterus), suggesting that coumestrol failed to stimulate significant cellular hyperplasia and DNA synthesis even when administered in a sustained fashion under these experimental conditions.
To further characterize the uterotropic response patterns to orally administered coumestrol, we also assessed the effects of this phytoestrogen on cytosolic and nuclear ER and nuclear type II binding site levels 72 hr after oral administration (Fig. 9) . These data essentially confirmed the injection studies (Figs. 5 and 6 ) in that oral administration of coumestrol also failed to cause accumulation of nuclear ER or deplete cytosolic ER. In fact, coumestrol treatment resulted in a three-to fourfold induction in the level of cytosolic ER, as was the case for the coumestrol injection studies. That nuclear type II sites were not stimulated by coumestrol treatment (Fig. 9) is consistent with the observation that uterine hyperplasia and DNA synthesis was not stimulated by coumestrol under these conditions (see legend to Figure 8 ). (Figs. 5, 6 , and 9), we suspected that subcutaneous or oral exposure to this phytoestrogen may alter the uterotropic response to estrogenic steroids. To evaluate this possibility, immature, ovariectomized rats were treated orally with vehicle (controls) or coumestrol (250 pg/mL) for 5 days before receiving three daily subcutaneous injections of various doses of estradiol (0.01-10 pg) and uterine weight was determined 24 hr after the last injection. Coumestrol pretreatment increased uterine sensitivity to estradiol as the response of the coumestrol pretreated uterus to doses of estradiol greater than 0.1 pg/day was significantly (p <0.05) greater than that observed in the vehicle pretreated controls. Therefore, coumestrol induction of ER during the 5-day pretreatment period significantly enhanced uterine sensitivity to estradiol.
Discussion
A major focus of our laboratory over the past decade has been estrogen regulation of normal and abnormal cell growth and proliferation. Our efforts have led to the identification of a bioflavonoid metabolite (MeHPLA) as an important cell growth regulating agent (9, 14) . MeHPLA is an endogenous ligand for nuclear type II sites (14) , and occupancy of this site by MeHPLA and bioflavonoids such as luteolin and quercetin appears to inhibit estrogen stimulation of uterine growth in the rat and mammary tumor growth in mice (8, 9, 14) . Subsequent studies demonstrate a direct correlation exists between the occupancy of type II sites by flavonoids such as luteolin, quercetin, and dihydroxybenzylidine acetophenone and the inhibition of breast (8-10), colorectal (11), pancreatic (12, and ovarian cancer (13) as well as the inhibition of leukemia (42) and lymphoblastoid cell proliferation (43) . These bioflavonoids do not bind to the ER (8), suggesting that the antiestrogenic and/or inhibitory effects of these compounds on cellular proliferation are mediated through type II sites. Therefore, it is likely that dietarily derived bioflavonoids inhibit normal and abnormal cell growth through this mechanism as well.
Conversely, isoflavonoids such as coumestrol, genistein, and daidzein have been described as estrogens, antiestrogens, and anticarcinogens because of their abilities to bind to ER in estrogen target cells (44) (45) (46) (47) (48) , even though these compounds inhibit the proliferation of ER negative breast cancer cells (49) . This former assumption has led to the generally accepted hypothesis that consumption of isoflavonoids may prevent breast or prostate cancer because these phytoestrogens compete with ovarian estradiol for ER, thus reducing exposure to the more active endogenous estrogenic hormones (7, 46, 48) . This line of reasoning was offered as an explanation as to why Japanese women, who have higher circulating levels of less potent, short-acting estrogens such as estriol and estrone, have a lower incidence of breast cancer than their American counterparts (50) . Although these hypotheses regarding the protective effects of the so-called weak or impeded estrogens are logical, they are not necessari- Hours after Injection Figure 8 . Effects of orally administered coumestrol on uterine growth in the rat. Ovariectomized rats were treated with 100 pg/mL coumestrol dissolved in drinking water containing 2% Tween 80 (vehicle). Controls received water-Tween 80 vehicle and uterine wet and dry weights were determined at the indicated times (0-96 hr) after treatment. The uterine DNA content (not shown in graph) after 72 hr of coumestrol treatment (242 pg/uterus) was not different from that measured in uteri from controls (217 pg/uterus). Data are means ± SEM.
ly supported by animal studies. It is well documented that estriol and estradiol-17ci are very weak estrogens incapable of stimulating cellular hyperplasia, when exposure is acute (single injection). However, chronic exposure to estriol or estradiol-17a via multiple injection or subcutaneous implant causes uterine cellular hypertrophy, hyperplasia, and mammary cancer in rodents in a manner analogous to that achieved with estradiol (28) (29) (30) (31) 51) . This is a likely paradigm for coumestrol, daidzein, and genistein if their pharmacology and mechanism of action are similar to those of other short acting estrogens (28) (29) (30) 51) .
Although some investigators have suggested that coumestrol, daidzein, and other related phytoestrogens may prevent cancer because these compounds inhibit malignant cell proliferation in vitro (52, 53) and dimethylbenz[a]anthracene (DMBA) induction of mammary tumors in the rat (54) , these phytoestrogens do not inhibit the growth of established DMBA-induced mammary tumors (55) , and their effects on the growth of other types of tumors in animals remains to be established. In fact, there is a paucity of experimental data directly demonstrating that phytoestrogens inhibit tumor growth in vivo. On the other hand, it is well documented that sustained exposure to phytoestrogens during the neonatal period is associated with persistent vaginal cornification, cervico-vaginal pegs and downgrowths, and uterine squamous metaplasia, which mimics that observed after exposure to diethylstibestrol (56, 57 (Fig. 1) . That coumestrol and daidzein displayed much higher affinities for nuclear type II sites (Kd 5-10 nM) than for the ER suggests that type II sites might be occupied in vivo at concentrations where these compounds will not bind to ER. This is currently being evaluated.
The ability of isoflavonoids to interact with both the ER and nuclear type II sites suggest that these compounds may display mixed agonist/antagonist activities. At lower concentrations (<100 nM) coumestrol may occupy nuclear type II sites (Kd 10 nM) and inhibit cell proliferation, as we have shown for luteolin and quercetin (8) Although recent studies demonstrate that oral administration of coumestrol increased uterine wet and dry weight, nuclear ER levels, and uterine progesterone receptor content in intact, immature rats, uterine DNA content was not determined in these studies (15) (16) (17) , and whether coumestrol stimulated cellular hyperplasia remains to be resolved. Therefore, even though coumestrol appeared to behave as a complete estrogen in these experiments, the animals were dosed with the phytoestrogen over a number of days, and it is possible that ovarian-derived estrogen contributed to the observed stimulation of uterine growth and progesterone receptor content as these animals reached puberty. The present studies using the immature, ovariectomized rat support this contention. Although coumestrol administration by single or multiple injection (Figs. 2-4 (28, 29) . It is more likely that the coumestrol-induced increase in uterine wet and dry weight in our studies in ovariectomized animals reflected increases in water and protein content. Studies by Yamazaki Figure 6 where injection of immature, ovariectomized rats with estradiol resulted in the classical cytosolic ER depletion and nuclear ER accumulation and retention patterns which precede estradiol stimulation of uterine growth in immature (28, 29) or adult, ovariectomized rats (29) (30) (31) 35) . Since sustained nuclear occupancy by the ER-estrogen complex is generally thought to be required for cellular hyperplasia and DNA synthesis (28) (29) (30) (31) , it is not surprising that coumestrol failed to stimulate uterine cellular hyperplasia (DNA content) under these experimental conditions in ovariectomized rats.
Even more surprising was the observation that subcutaneous injection (Figs. 5 and 6) or oral administration of coumestrol (Fig. 9 ) increased cytosolic ER levels two-to threefold without causing significant cytosolic depletion and nuclear accumulation of ER or induction of nuclear type II sites, which are characteristic responses to estrogenic hormone administration (22, 23, 28) . These latter two nuclear events are typically correlated with estrogenic stimulation of cellular DNA synthesis and proliferation (28) (29) (30) 35) . These findings also imply that coumestrol may be an atypical estrogen which does not modulate ER or type II site function in a manner analogous to that of estradiol (Figs. 6 and 9) , estriol, or estradiol-17a (28) (29) (30) (31) in the ovariectomized rat uterus. Consequently, although recent studies suggest nuclear ER are elevated in coumestroltreated, intact, immature rats (15) (16) (17) , this ER could have been occupied by ovarian estrogen and not necessarily coumestrol.
Although it is certainly possible that much higher doses of coumestrol would Volume 103, Number 6, June 1995 have significantly altered ER dynamics to stimulate true uterine growth in the present studies, injection of 500 pg of coumestrol under the conditions described in Figures 5 and 6 also failed to cause cytosolic ER depletion and/or nuclear ER accumulation and DNA synthesis (not shown). Nevertheless, 500 pg of coumestrol stimulated cytosolic ER in a manner similar to that shown obtained with 100 pg of this phytoestrogen (Fig 5) . Therefore, increasing the dose level of coumestrol fivefold (-10 mg/kg body weight) failed to alter the response profiles at these short times (1-3 days) after injection. Whether this increase in cytosolic ER concentration after coumestrol treatment reflects phytoestrogeninduced ER activation, ER phosphorylation, and/or the stimulation of ER gene transcription remains to be resolved (61, 62) .
Regardless of the mechanism by which coumestrol increases ER concentration in the uterus, it appears that this isoflavonoid may enhance the sensitivity of this target tissue to estradiol. The data in Figure 10 demonstrate that coumestrol pretreatment significantly shifted the dose-response curve for estradiol, and it is likely that coumestrol induction of cytosolic ER as shown in Figures 5 and 6 by causing ER activation or phosphorylation (60, 61) or by enhancing ovarian release of estrogen. If this is the case, one might anticipate that the observed estrogenicity or antiestrogenicity of dietarily derived phytoestrogens such as coumestrol may be different in premenopausal and postmenopausal women. This being the case, it is difficult to speculate as to whether phytoestrogens such as coumestrol will prevent and/or protect against cancer by competing with ovarian estrogens for ER as suggested (5, 6) or whether continuous consumption of antiestrogenic flavonoids such as luteolin and quercetin which inhibit the growth of a broad spectrum of rodent (8, 9) and human cancers in vitro and in vivo (10-13) will reduce cancer incidence in humans by antagonism at the level of the type II site. Studies designed to accurately define the estrogenicity and antiestrogenicity of dietarily derived isoflavonoids and flavonoids and potential interactions with one another and endogenous estrogens and androgens in these experimental systems will be required to adequately address these issues.
